BioDelivery's Products Attract Growing Interest

Shares of BioDelivery Sciences (BDSI) broke above the $5 dollar barrier for the first time in a little while after a Tuesday morning press release announced that the company has received a $1.3 million grant from the Walter Reed Army Institute of Research.

The grant, according to the press release, is [quoted directly from the release] "for Bioral Amphotericin B, an oral formulation of the fungicidal treatment amphotericin B in BDSI’s patented Bioral drug delivery technology, to further study the formulation in the treatment of Cutaneous Leishmaniasis."

The money amount is fairly insignificant, but what should be taken away from this PR is that there is growing interest in BioDelivery's products and the BEMA drug delivery technology.

I still like BDSI as a long term growth stock.

Disclosure: Long BDSI.

Comments

[protrder:]

BDSI is way undervalued right now and it's never been a better time to buy. I am loading up on any dips.

Oct 07 12:59 PM